Chemed price target raised to $610 from $587 at RBC Capital

RBC Capital raised the firm’s price target on Chemed to $610 from $587 and keeps an Outperform rating on the shares. While the analyst attributes the post-earnings share weakness to management’s commentary on modest revenue softness in March, which overshadowed an otherwise strong quarter, the firm continues to believe both the VITAS and RR segments are well positioned to gain market share over the long term, the analyst tells investors in a research note.